9.00 USD
▲+0.03+11.66%
盘后 8.10 +0.50%
2026-08-03
市值
$587.70M
市盈率
67.33
EPS
-3.22
股息率
—
52 周区间
6.06 – 14.51
成交量
3.03M
Beta
1.75
目标价
14.79
52W 低 6.0652W 高 14.51
价格走势
公司简介
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs , including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, suc...